SIRT1 and cancer: Meanwhile, the IC50 concentration of cisplatin for cancer cells decreased significantly from 6.34 ug/ml in control cells and 1.61 ug/ml in SIRT1 si-RNA-transfected cells, indicating that SIRT1 silencing significantly enhanced the chemosensitivity of H292 cells to cisplatin treatment.